MASI Quote, Financials, Valuation and Earnings

Accuray has a net margin of -58.2% compared to Masimo's net margin of 2.18%. Masimo's return on equity of -23.05% beat Accuray's return on equity of -9.63%.

Masimo has a consensus price target of $193.76, signalling upside risk potential of 15.19%. On the other hand Accuray has an analysts' consensus of $6.13 which suggests that it could grow by 234.7%. Given that Accuray has higher upside potential than Masimo, analysts believe Accuray is more attractive than Masimo.

Masimo has a beta of 1.035, which suggesting that the stock is 3.537% more volatile than S&P 500. In comparison Accuray has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.041%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Accuray pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $600.7M, which are larger than Accuray quarterly revenues of $116.2M. Masimo's net income of -$349.6M is lower than Accuray's net income of $2.5M. Notably, Masimo's price-to-earnings ratio is 116.80x while Accuray's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.35x versus 0.41x for Accuray. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of -58.2% compared to Masimo's net margin of 12.41%. Masimo's return on equity of -23.05% beat Boston Scientific's return on equity of 8.96%.

Masimo has a consensus price target of $193.76, signalling upside risk potential of 15.19%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 19%. Given that Boston Scientific has higher upside potential than Masimo, analysts believe Boston Scientific is more attractive than Masimo.

Masimo has a beta of 1.035, which suggesting that the stock is 3.537% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $600.7M, which are smaller than Boston Scientific quarterly revenues of $4.6B. Masimo's net income of -$349.6M is lower than Boston Scientific's net income of $566M. Notably, Masimo's price-to-earnings ratio is 116.80x while Boston Scientific's PE ratio is 77.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.35x versus 8.62x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of -58.2% compared to Masimo's net margin of 7.87%. Masimo's return on equity of -23.05% beat Merit Medical Systems's return on equity of 9.36%.

Masimo has a consensus price target of $193.76, signalling upside risk potential of 15.19%. On the other hand Merit Medical Systems has an analysts' consensus of $118.20 which suggests that it could grow by 19.47%. Given that Merit Medical Systems has higher upside potential than Masimo, analysts believe Merit Medical Systems is more attractive than Masimo.

Masimo has a beta of 1.035, which suggesting that the stock is 3.537% more volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.607%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $600.7M, which are larger than Merit Medical Systems quarterly revenues of $355.2M. Masimo's net income of -$349.6M is lower than Merit Medical Systems's net income of $27.9M. Notably, Masimo's price-to-earnings ratio is 116.80x while Merit Medical Systems's PE ratio is 48.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.35x versus 4.33x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -58.2% compared to Masimo's net margin of 26.88%. Masimo's return on equity of -23.05% beat ResMed's return on equity of 25.56%.

Masimo has a consensus price target of $193.76, signalling upside risk potential of 15.19%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 20.17%. Given that ResMed has higher upside potential than Masimo, analysts believe ResMed is more attractive than Masimo.

Masimo has a beta of 1.035, which suggesting that the stock is 3.537% more volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.92% to investors and pays a quarterly dividend of $0.53 per share. Masimo pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo quarterly revenues are $600.7M, which are smaller than ResMed quarterly revenues of $1.3B. Masimo's net income of -$349.6M is lower than ResMed's net income of $344.6M. Notably, Masimo's price-to-earnings ratio is 116.80x while ResMed's PE ratio is 26.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.35x versus 6.71x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.